PFE

Um Fizer, you know, in my opinion, Fizer is like the best like biotech in terms of an overall package valuation dividend wise right now. So, yeah, we're we are a little heavy on it, but I think that's okay. It's only around 4% of the portfolio.

So, Fizer, again, it's like the overall best biotech in terms of valuation and dividend. I think it's a solid biotech uh pharmaceutical play, whatever you want to call it,

I love it because it's so out of favor you can't give the stock away. Um you're getting a 6% dividend yield while you wait for them to turn the boat. They had a COVID windfall.

They used the money to buy CGEN 43 billion. That's going to do10 billion dollars a year. They cut 7.2 billion in cost. People are afraid of the loss of exclusivity from some of their major drugs.

It's lower than expected. And they have a GLP1 with the Metera coming out uh 2728, which is once a month GLP uh which you can take as a pill and subcutaneous. So maybe they'll be late to the party, maybe it'll be revolutionary.

We don't know. But in the meantime, costs are out. The oncology franchise pipeline is robust. All the bad news is priced in. You you got you're you know, I learned early on in this business, if your downside is protected, your upside will take care of itself.

And if I'm paid 6% to wait while this thing, you know, uh recovers over time. That's a good thing, not a bad thing.